Paroxysmal Nocturnal Hemoglobinuria Drug Market, By Treatment (Medication, Supplements, Blood Transfusion and Bone Marrow Transplant), By Drugs (Eculizumab and Ravulizumab), By Route of Administration (Oral and Parenteral), By End User (Hospitals, Homecare and Specialty Clinics), By Country, and By Region Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Paroxysmal Nocturnal Hemoglobinuria Drug Market size was valued at USD 3,470.2 Million in 2022, expanding at a CAGR of 13.8% from 2023 to 2030.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and potentially life-threatening blood disorder characterized by the destruction (hemolysis) of red blood cells and the presence of abnormal red blood cells in the bloodstream. This condition arises due to the overactivation of the complement system, a crucial component of the body\'s immune system responsible for eliminating foreign substances. PNH is primarily triggered by a genetic mutation that impacts the surface proteins of red blood cells.
Paroxysmal Nocturnal Hemoglobinuria Drug Market- Market Dynamics
- Growing regulatory approvals and R&D drives market growth
The global market for medications to treat paroxysmal nocturnal hemoglobinuria (PNH) relies significantly on regulatory approvals granted by agencies such as the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and other international regulatory bodies. The approval of drugs like eculizumab and ravulizumab has played a pivotal role in establishing their presence in the market and ensuring patient access to these treatments. Furthermore, ongoing research and development efforts in the PNH field are focused on discovering new therapy options and improving existing treatments. This includes exploring combination therapies, developing innovative targeted therapeutics, and alternative methods of drug administration. These advancements and innovations contribute to the growth and evolution of the PNH pharmaceutical industry.
Paroxysmal Nocturnal Hemoglobinuria Drug Market- Key Insights
- The Global Paroxysmal Nocturnal Hemoglobinuria Drug Market is categorized based on treatment, therapy type, distribution channel, and region.
- The market is divided into three categories based on treatment: blood transfusion, complement inhibitors, and others. The blood transfusion segment is expected to dominate the market over the forecast period.
- Blood transfusions play a crucial role in managing paroxysmal nocturnal hemoglobinuria by replenishing red blood cells and alleviating anemia, a common complication of the condition. As a result, the blood transfusion segment is anticipated to witness significant growth during the forecast period.
Paroxysmal Nocturnal Hemoglobinuria Drug Market- Segmentation Analysis:
The Global Paroxysmal Nocturnal Hemoglobinuria Drug Market encompasses various segments, including treatment, drugs, route of administration, end user, and region.
Within the treatment category, it is further divided into medication, supplements, blood transfusion, and bone marrow transplants. Among these, the blood transfusion segment is poised to hold a dominant position in the market throughout the forecast period. Blood transfusion plays a pivotal role in mitigating the symptoms of anemia, which is a significant consequence of PNH. The condition, if left untreated, can lead to severe complications such as thrombosis and even prove fatal. To address these anemic symptoms effectively, individuals with PNH often require blood transfusions. During these transfusions, patients receive donated blood or blood products, making it a crucial aspect of PNH management and consequently propelling the growth of this market segment.
Paroxysmal Nocturnal Hemoglobinuria Drug Market- Competitive Landscape:
Leading companies in the global pharmaceutical industry are actively investing in research and development to broaden their range of products and services. Additionally, these market players are forging strategic partnerships and collaborations to foster growth and innovation. Key players in the pharmaceutical sector include companies like Pfizer, Novartis, Roche, Johnson & Johnson, GlaxoSmithKline, and Merck. These industry giants are at the forefront of developing new drugs and therapies to address a wide range of medical conditions and diseases, from cancer to infectious diseases and chronic illnesses. Their commitment to research, innovation, and collaboration is driving advancements in healthcare and improving patient outcomes.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET KEY PLAYERS
- Ra Pharmaceuticals Inc
- CinnaGen Co
- Akari Therapeutics Plc
- Alexion Pharmaceuticals Inc
- Apellis Pharmaceuticals
- Abbott
- NorthStar Rx LLC
- Alnylam Pharmaceuticals Inc
- Hoffmann-La Roche Ltd
- Novartis AG
- Regeneron Pharmaceuticals Inc
- BIOCAD
- Samsung Bioepis
- Amyndas Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- LGM Pharma.
- Lannett
- Achillion Pharmaceuticals Inc
- Amgen Inc
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY TREATMENT
- Medication
- Supplements
- Blood Transfusion
- Bone Marrow Transplant
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY DRUGS
- Eculizumab
- Ravulizumab
- Others
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY ROUTE OF ADMINISTRATION
- Oral
- Parenteral
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY END USER
- Hospitals
- Homecare
- Specialty Clinics
- Others
GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Treatment
2.1.2. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Drugs
2.1.3. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Route of Administration
2.1.4. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by End User
2.1.5. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Country
2.1.6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Region
2.2. Competitive Insights
3. Paroxysmal Nocturnal Hemoglobinuria Drug Key Market Trends
3.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Paroxysmal Nocturnal Hemoglobinuria Drug Market Opportunities
3.4. Paroxysmal Nocturnal Hemoglobinuria Drug Market Future Trends
4. Paroxysmal Nocturnal Hemoglobinuria Drug Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Paroxysmal Nocturnal Hemoglobinuria Drug Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Landscape
6.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Paroxysmal Nocturnal Hemoglobinuria Drug Market – By Treatment
7.1. Overview
7.1.1. Segment Share Analysis, By Treatment, 2022 & 2030 (%)
7.1.2. Medication
7.1.3. Supplements
7.1.4. Blood Transfusion
7.1.5. Bone Marrow Transplant
8. Paroxysmal Nocturnal Hemoglobinuria Drug Market – By Drugs
8.1. Overview
8.1.1. Segment Share Analysis, By Drugs, 2022 & 2030 (%)
8.1.2. Eculizumab
8.1.3. Ravulizumab
8.1.4. Others
9. Paroxysmal Nocturnal Hemoglobinuria Drug Market – By Route of Administration
9.1. Overview
9.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
9.1.2. Oral
9.1.3. Parenteral
10. Paroxysmal Nocturnal Hemoglobinuria Drug Market – By End User
10.1. Overview
10.1.1. Segment Share Analysis, By End User, 2022 & 2030 (%)
10.1.2. Hospitals
10.1.3. Homecare
10.1.4. Specialty Clinics
10.1.5. Others
11. Paroxysmal Nocturnal Hemoglobinuria Drug Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
11.2. North America
11.2.1. Overview
11.2.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
11.2.4. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.2.5. North America Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.2.6. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.2.7. North America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.3.9. Italy
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.3.9.3. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.3.9.4. Italy Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.3.9.6. Italy Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.3.10. United Kingdom
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.3.10.3. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.3.10.4. United Kingdom Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.3.11. France
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.3.11.3. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.3.11.4. France Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.3.11.5. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.3.11.6. France Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.3.12. Russia
11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.3.12.2. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.3.12.3. Russia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.3.12.5. Russia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.3.13. Netherlands
11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.3.13.2. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.3.13.3. Netherlands Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.3.13.5. Netherlands Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.3.14. Sweden
11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.3.14.2. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.3.15. Poland
11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.3.15.2. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.3.15.3. Poland Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.3.15.5. Poland Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.3.16. Rest of Europe
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.3.16.3. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.3.16.4. Rest of the Europe Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Asia Pacific
11.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
11.4.4. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.4.5. Asia Pacific Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.4.7. Asia Pacific Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.4.8. India
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.4.8.3. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.4.8.4. India Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.4.8.5. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.4.8.6. India Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.4.9. China
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.4.9.3. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.4.9.4. China Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.4.9.5. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.4.9.6. China Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.4.13. Thailand
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.4.13.3. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.4.13.4. Thailand Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.4.13.6. Thailand Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.4.14. Indonesia
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.4.14.3. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.4.14.4. Indonesia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.4.14.6. Indonesia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.5. Latin America
11.5.1. Overview
11.5.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Latin America
11.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
11.5.4. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.5.5. Latin America Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.5.7. Latin America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.6. Middle East and Africa
11.6.1. Overview
11.6.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Middle East and Africa
11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
11.6.4. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.6.5. Middle East and Africa Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
12. Key Vendor Analysis- Paroxysmal Nocturnal Hemoglobinuria Drug Industry
12.1. Competitive Dashboard
12.2. Company Profiles
12.2.1. Ra Pharmaceuticals Inc
12.2.2. CinnaGen Co
12.2.3. Akari Therapeutics Plc
12.2.4. Alexion Pharmaceuticals Inc
12.2.5. Apellis Pharmaceuticals
12.2.6. Abbott
12.2.7. NorthStar Rx LLC
12.2.8. Alnylam Pharmaceuticals Inc
12.2.9. F. Hoffmann-La Roche Ltd
12.2.10. Novartis AG
12.2.11. Regeneron Pharmaceuticals Inc
12.2.12. BIOCAD
12.2.13. Samsung Bioepis
12.2.14. Amyndas Pharmaceuticals
12.2.15. Teva Pharmaceutical Industries Ltd.
12.2.16. LGM Pharma.
12.2.17. Lannett
12.2.18. Achillion Pharmaceuticals Inc
12.2.19. Amgen Inc
13. 360 Degree Analyst View
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
